1. Home
  2. GENC vs VYGR Comparison

GENC vs VYGR Comparison

Compare GENC & VYGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Gencor Industries Inc.

GENC

Gencor Industries Inc.

HOLD

Current Price

$13.62

Market Cap

205.4M

Sector

Industrials

ML Signal

HOLD

Logo Voyager Therapeutics Inc.

VYGR

Voyager Therapeutics Inc.

HOLD

Current Price

$4.03

Market Cap

226.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GENC
VYGR
Founded
N/A
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Construction/Ag Equipment/Trucks
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
205.4M
226.8M
IPO Year
N/A
2015

Fundamental Metrics

Financial Performance
Metric
GENC
VYGR
Price
$13.62
$4.03
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
6
Target Price
$16.00
$17.00
AVG Volume (30 Days)
31.6K
375.7K
Earning Date
12-09-2025
11-10-2025
Dividend Yield
N/A
N/A
EPS Growth
7.92
N/A
EPS
1.07
N/A
Revenue
$115,437,000.00
$31,316,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$71.78
P/E Ratio
$12.79
N/A
Revenue Growth
2.01
N/A
52 Week Low
$10.80
$2.65
52 Week High
$17.40
$5.96

Technical Indicators

Market Signals
Indicator
GENC
VYGR
Relative Strength Index (RSI) 60.57 46.28
Support Level $13.12 $3.89
Resistance Level $13.60 $4.19
Average True Range (ATR) 0.44 0.19
MACD 0.12 0.00
Stochastic Oscillator 78.33 50.57

Price Performance

Historical Comparison
GENC
VYGR

About GENC Gencor Industries Inc.

Gencor Industries Inc and its subsidiaries is a manufacturer of heavy machinery used in the production of highway construction materials and environmental control equipment. The Company has one reporting segment, equipment for the highway construction industry. The firm's principal products include asphalt plants, combustion systems, hot mix asphalt plants, fluid heat transfer systems, and asphalt pavers.

About VYGR Voyager Therapeutics Inc.

Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.

Share on Social Networks: